Urgent Notice to All Conference Participants

It has been brought to our attention that EHS Housing has recently been cold calling our speakers offering accommodation for a named Fusion conference. Please note that we have no association with EHS Housing and they are acting on our behalf without our permission. We strongly advise that any calls from EHS Housing are ignored or ended immediately. If you are contacted by EHS Housing, please notify us immediately.

All Fusion registration fees are inclusive of accommodation (for three fixed nights) and reservations are handled internally, entirely by Fusion Conferences. If you have any questions concerning your accommodation, please contact Fusion Conferences directly via admin@fusion-conferences.com.

Home > Past Conferences > Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases Conference

The registration process for this conference has now closed.

Registration Deadlines

Early bird – expired

Talk Submission – expired

Poster Submission – expired

Last Chance – expired

Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases Conference

01 Jun 2018 - 04 Jun 2018

Nassau, Bahamas

The conference registration date has past

Synopsis

Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease, which affects over 5 million people in the US and over 35 million people worldwide. Currently, only four drugs are approved for alleviating symptoms in AD patients, and no new therapy has been approved for AD since 2003. Other related neurodegenerative diseases such as Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are also age-dependent and lack effective therapies. Hence, finding cures for AD and other related neurodegenerative diseases is urgent and various approaches should be actively pursued. This planned conference intends to bring leading scientists and clinicians from all over the world to present their unpublished observations or findings to attendees and to share their vision or prospects on translational research. We expect that some presenters, either by talks or posters, will discuss our current state of knowledge in disease mechanisms, novel targets or approaches for identifying new therapeutic targets, and biomarkers for diagnosis or treatment readouts. We will also invite speakers who are conducting later stages of drug discoveries, including presentations of clinical trial results. The talks and poster presentations will include the most updated therapeutic strategies, newly discovered therapeutic targets, and recent clinical developments at various stages in the area of Alzheimer’s and related neurodegenerative diseases.  

Key topics of discussion will include:
1) BACE1 inhibitors and/or γ-secretase modulators for reducing amyloid deposition 
2) active and passive vaccination for enhancing clearance of amyloid plaques
3) Vaccines for reducing tau pathology
4) Antisense approaches for AD, PD and ALS therapy
5) Neural stem cell approaches for neurodegeneration
6) Inflammatory modulators for neurodegeneration.

The significance of having this conference is to provide a unique forum for the research community focusing on translational studies geared towards therapies in AD and related neurodegenerative diseases to come together and to discuss the latest advances and the future challenges in the field.  It will also facilitate interactions between junior scientists and leading investigators in a relatively small conference setting. 

Student Offer

Take advantage of this fantastic opportunity for students! Register an academic at the earlybird rate of $1,823 and bring a student for only $850. Unfortunately, Postdocs are not eligible. Both registration packages include; accommodation for the 01, 02, 03 June 2018 (on a shared basis for students) and a 24hour all-inclusive food and beverage package for the conference period. Once registered, please contact Jack Peters (jack@fusion-conferences.com) to obtain a special registration link for your student.

Plenary Speakers

David Holtzman (Washington University)
Li-Huei Tsai (MIT) 

Invited Speakers

Elizabeth M. Bradshaw (Center for translational & Computational Neuroimmunology Columbia University Medical Center)
Matt Blurton-Jones
(University of California, Irvine)
Guy Brown (University of Cambridge) 
Guojun Bu
(Mayo Clinic)
Rita Cacace (University of Antwerp)
Damian Crowther (AstraZeneca)
Philip De Jager (Center for translational & Computational Neuroimmunology Columbia University Medical Center)
Charles Glabe (University of California, Irvine)
Yadong Huang (Gladstone Institute)
Sally Ishizaka (Eisai) 
Orly Lazarov (University of Illinois at Chicago)
Yueming Li (Memorial Sloan Kettering Cancer Center)
Richard Mayeux (Taub Institute at Columbia University)
Jennifer Pocock (University College London)
Domenico Praticò (Temple University)
Nikolaos Robakis (Mount Sinai)
Gerard D. Schellenberg (University of Pennsylvania Perelman School of Medicine)
Sangram S. Sisodia (The University of Chicago)
Giulio Taglialatela (University of Texas Medical Branch)
Giuseppinna Tesco (Tufts University)
Taisuke Tomita
(University of Tokyo)
Jeffery M. Vance (University of Miami)
Robert Vassar (Northwestern University)
Huaxi Xu (Sanford Burnham Prebys Medical Discovery Institute)
Gang Yu (UT Southwestern)
Xiongwei Zhu (Case Western Reserve University)

Sponsors

Sponsors

Programme

FRIDAY 1st JUNE 2018

14:00 – 14:45

Registration & Reception

14:00 – 14:45

Group Welcome Lunch

14:45 – 15:00

Opening Comments

PERSPECTIVES OF AD PATHOGENESIS
Riqiang Yan and Peter St George-Hyslop

15:00 – 15:45

David Holtzman Washington University in St. Louis

APOE: ROLE IN AMYLOID-β ACCUMULATION AND IN TAU-MEDIATED NEURODEGENERATION

15:45 – 16:00

Zhengui Xia
University of Washington

GENE-ENVIRONMENT INTERACTION BETWEEN LEAD AND APOLIPOPROTEIN E4 CAUSES COGNITIVE BEHAVIOR DEFICITS IN MICE

16:00 – 16:30

Guojun Bu
Mayo Clinic

PATHOBIOLOGY AND THERAPEUTIC TARGETING OF APOE IN ALZHEIMER’S DISEASE

16:30 – 17:00

Sangram Sisodia
University of Chicago

MODULATION OF AMYLOID DEPOSITION AND NEUROINFLAMMATION BY THE MICROBIOME

17:00 – 17:30

Refreshments

STEM CELLS IN AD
Peter St. George-Hyslop

17:30 – 18:00

Orly Lazarov
University of Illinois at Chicago

THERAPEUTIC AND DIAGNOSTIC POTENTIAL OF CREB IN ALZHEIMER’S DISEASE

18:00 – 18:30

Mathew Blurton-Jones
University of California, Irvine

USING iPSC-DERIVED MICROGLIA AND HUMANIZED MICE TO STUDY THE FUNCTIONAL GENOMICS OF ALZHEIMER'S DISEASE

18:30 – 19:00

Yadong Huang
Gladstone Institute

ALZHEIMER'S DISEASE MODELING AND DRUG SCREENING USING HUMAN IPSCS

19:00 – 19:30

Giulio Taglialatela
University of Texas Medical Branch at Galveston

NEURAL STEM CELLS PROMOTE SYNAPTIC RESILIENCE TO DAMAGING Ab AND TAU OLIGOMERS VIA EXOSOME DELIVERY OF SELECTED MIRNA CARGOES

19:30 – 20:00

Riqiang Yan
University of Connecticut

ENHANCING NEUROGENESIS TO REVERSE NEURONAL LOSS IN AD MOUSE MODELS

20:00

Group Dinner

SATURDAY 2nd JUNE 2018

07:00 – 08:30

Breakfast

GENETICS AND EPIGENETICS OF AD
Nikolaos Robakis

08:30 – 09:00

Gerard Schellenberg
University of Pennsylvania Perelman School of Medicine

GENETIC STUDIES OF ALZHEIMER'S DISEASE; IDENTIFICATION OF THERAPEUTIC TARGETS

09:00 – 09:30

Jeffery Vance
University of Miami Health System

IDENTIFYING A PROTECTIVE FACTOR FOR APOE4

09:30 – 10:00

Richard Mayeux
Taub Institute at Columbia University

GENETIC AND GENOMIC CONTRIBUTIONS TO ALZHEIMER’S DISEASE FROM THE CARIBBEAN ISLANDS

10:00 – 10:30

Rita Cacace
University of Antwerp

EXPLORING THE MISSING GENETICS OF EARLY ONSET ALZHEIMER’S DISEASE: INSIGHTS FROM GENOMIC STUDIES IN AUTOSOMAL DOMINANT FAMILIES

10:30

Group Photo & Refreshments

10:45 – 16:15

Free Time

12:30 – 15:00

Snorkel Trip (Signups required in advance)

MOLECULAR MECHANISM OF AD PATHOGENESIS
Guojun Bu

16:15 – 16:45

Peter St George-Hyslop
University of Toronto

PHYSIOLOGICAL AND PATHOLOGICAL PHASE SEPARATION OF FUS IS REGULATED BY METHYLATION OF COOPERATIVE CROSS-DOMAIN CATION-PI INTERACTIONS AND INTERACTION WITH TNPO1

16:45 – 17:15

Domenico Praticò
Temple University

THE LEUKOTRIENES PATHWAY AS A VIABLE THERAPEUTIC TARGET FOR TAUOPATHIES

17:15 – 17:45

Charles Glabe
University of California, Irvine

PLX3397, A CSF1R/C-KIT INHIBITOR, ABLATES MICROGLIA AND BLOCKS THE ACCUMULATION OF INTRANEURONAL AMYLOID AND NEURITIC PLAQUES IN 5XFAD MICE

17:45 – 18:15

Refreshments

18:15 – 18:30

Cara Croft
University of Florida

rAAV-MEDIATED BRAIN SLICE CULTURE MODELS TO DEVELOP TAU-BASED THERAPEUTICS

18:30 – 19:00

Sally Ishizaka
Eisai

IMMUNO-DEMENTIA: HUMAN GENETICS-GUIDED DRUG DISCOVERY IN ALZEIMER'S DISEASE

19:00 – 19:30

Taisuke Tomita
University of Tokyo

NOVEL STRATEGIES FOR FACILITATION OF AMYLOID CLEARANCE IN THE BRAIN

19:30

Group Dinner

SUNDAY 3rd JUNE 2018

07:00 – 08:30

Breakfast

NEURO-INFLAMMATION IN AD
Robert Vassar

08:30 – 09:15

Li-Huei Tsai
MIT

DECIPHERING THE IMMUNE RESPONSE OF MICROGLIA IN NEURODEGENERATION USING SINGLE-CELL RNA-SEQUENCING

09:15 – 09:45

Guy Brown
University of Cambridge

NEURODEGENERATION CAUSED BY MICROGLIAL PHAGOCYTOSIS OF NEURONS

09:45 – 10:15

Elizabeth M. Bradshaw
Center for translational & Computational Neuroimmunology, Columbia University Medical Center

ARE CD33 SIALIC-ACID DEPENDENT BINDING PARTNERS THERAPEUTIC TARGETS FOR AD?

10:15 – 10:45

Refreshments

10:45 – 11:15

Damian Crowther
AstraZeneca

TREM2 METABOLISM AT THE CELL SURFACE: OPTIONS FOR THERAPEUTIC MODULATION

11:15 – 11:45

Jennifer Pocock
University College London

TREM2 VARIANTS; RAMIFICATIONS FOR MICROGLIAL FUNCTION

11:45 – 12:15

Philip L. De Jager
Center for translational & Computational Neuroimmunology, Columbia University Medical Center

POPULATION STRUCTURE OF HUMAN MICROGLIA: WHICH SUBSET OF MICROGLIA DO WE TARGET FOR TAU AND/OR AMYLOID PATHOLOGY?

12:15 – 17:30

Lunch at Leisure & Free Time

SECRETASES IN AD THERAPY
Huaxi Hu

17:30 – 18:00

Robert Vassar
Northwestern University

BACE1 AS A THERAPEUTIC TARGET FOR ALZHEIMER’S DISEASE

18:00 – 18:15

Brati Das
University of Connecticut Health Center

DELETION OF BACE1 IN ADULT AD MICE REVERSES AMYLOID DEPOSITION AND IMPROVES SYNAPTIC FUNCTION

18:15 – 18:45

Giuseppina Tesco
Tufts University

BACE1 UPS AND DOWNS: IMPLICATIONS FOR AD

18:45 – 19:15

Yueming Li
Memorial Sloan Kettering Institute

HYPOXIA AND GAMMA-SECRETASE

19:45

*Gala Dinner*

MONDAY 4th JUNE 2018

07:00 – 08:30

Breakfast

NOVEL TARGETS IN AD THERAPY
Charles Glabe

08:30 – 09:00

Huaxi Xu
Sanford Burnham Prebys Medical Discovery Institute

NOVEL ROLES FOR ALZHEIMER’S RISK GENE SORLA IN NEUROPROTECTION

09:00 – 09:30

Nikolaos Robakis
Mount Sinai School of Medicine

PS1-REGULATED NEUROPROTECTIVE NMDAR COMPLEXES ARE INACTIVATED BY FAD MUTANTS

09:30 – 10:00

Gang Yu
UT Southwestern

GAMMA-SECRETASE, GLIA/IMMUNE FUNCTION, AND ALZHEIMER’S DISEASE?

10:00 – 10:30

Refreshments

10:30 – 10:45

Ronald Davis
Scripps Research Institute Florida

SMALL MOLECULE PROBES TARGETING NEURONAL MITOCHONDRIAL DYNAMICS INCREASE ATP PRODUCTION, RESCUE OXIDATIVE STRESS AND AMYLOID BETA MEDIATED NEUROTOXICITY

10:45 – 11:15

Xiongwei Zhu
Case Western Reserve University

ABNORMAL MITOCHONDRIAL DYNAMICS AS A THERAPEUTIC TARGET OF ALZHEIMER DISEASE

11:15 – 11:30

Closing Comments by Peter St. George-Hyslop and Riqiang Yan

Speakers

Plenary Speakers

  • Dr. David Holtzman
    Professor and Chair, Washington University in St. Louis
  • Dr. Li-Huei Tsai
    Professor and Director, MIT

Invited Speakers

  • Prof. Dr. Taisuke Tomita
    Professor, Graduate School of Pharmaceutical Sciences, The University of Tokyo
  • Prof. Domenico Pratico
    Professor, Temple University
  • Dr. Sally Ishizaka
    Director, Immuno-Dementia, Eisai Inc.
  • Dr. Mathew Blurton-Jones
    Associate Professor, University of California, Irvine
  • Prof. Orly Lazarov
    Professor, The University of Illinois at Chicago
  • Dr. Charles Glabe
    Professor, UC Irvine
  • Prof. Guojun Bu
    Professor, Mayo Clinic
  • Prof. Gerard Schellenberg
    Professor, Perelman School of Medicine, University of Pennsylvania
  • Dr. Giuseppina Tesco
    Associate Professor, Tufts University
  • Prof. Dr. Robert Vassar
    Professor, Northwestern University
  • Prof. Gang YU
    Professor, University of Texas Southwestern Medical Center
  • Dr. Nikolaos Robakis
    Professor, Mount Sinai Medical Cemter
  • Prof. Xiongwei Zhu
    Professor, Case Western Reserve University
  • Dr. Elizabeth Bradshaw
    Assistant Professor, Center for translational & Computational Neuroimmunology Columbia University Medical Center
  • Dr. Damian Crowther
    Director, R&D, Neuroscience, AstraZeneca IMED Biotech Unit
  • Prof. Dr. Giulio Taglialatela
    Professor and Vice Chair, University of Texas Medical Branch
  • Prof. Guy Brown
    Professor, University of Cambridge
  • Dr. Rita Cacace
    Postdoc, University of Antwerp
  • Prof. Dr. Huaxi Xu
    Professor and Director of Neuroscience, Sanford Burnham Prebys Medical Discovery Institute
  • Prof. Yueming Li
    Professor, Memorial Sloan Kettering Cancer Center
  • Prof. Dr. Yadong Huang
    Senior Investigator/Professor, Gladstone Institutes/UCSF
  • Prof. Dr. Richard Mayeux
    Professor, Taub Institute at Columbia University
  • Prof. Dr. Jeff Vance
    professor, University of Miami
  • Dr. Jennifer Pocock
    Senior Lecturer, University College London Institute of Neurology
  • Prof. sangram sisodia
    Professor of Neurosciences, university of chicago
  • Prof. Philip De Jager
    Professor of Neurology, Columbia University Medical Center

Feedback

Sign In

Your feedback has been received.

Cant see images? See gallery on Flickr